Myeloid-Derived Suppressor Cells in Murine Retrovirus-Induced AIDS Inhibit T- and B-Cell Responses In Vitro That Are Used To Define the Immunodeficiency

Journal of Virology

Volumn 87, Issue 4, 2013, Pages 2058-2071

  Green, Kathy A ^a   Cook, W James ^a   Greena, William R ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; INTERLEUKIN 10; MONOCLONAL ANTIBODY;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; BONE MARROW CELL; CELL EXPANSION; CELL POPULATION; CELL PROLIFERATION; CELL SURFACE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREACTIVITY; IMMUNOREGULATION; IN VITRO STUDY; MALE; MITOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SPLEEN CELL; SUPPRESSOR CELL; T LYMPHOCYTE; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANIMALS; ANTIGENS, CD11B; ANTIGENS, LY; B-LYMPHOCYTES; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; MALE; MICE; MICE, INBRED C57BL; MONOCYTES; RECEPTORS, CHEMOKINE; RETROVIRIDAE; T-LYMPHOCYTES;

EID: 84873814690     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01547-12     Document Type: Article

References (108)

1. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J, Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJR, Klenerman P, Ahmed R, Freeman GJ, Walker BD. 2006. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443:350-354.
2. + T cells. J. Immunol. 180: 7757-7763.
3. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. 2006. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203:2223-2227.
4. + T cell survival in HIV infection. J. Exp. Med. 203:2281-2282.
5. Velu V, Titanji K, Zhu B, Husain S, Pladevega A, Lai L, Vanderford TH, Chennareddi L, Silvestri G, Freeman GJ, Ahmed R, Amara RR. 2009. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458:206-210.
6. + T cells leads to reversible immune dysfunction. Nat. Med. 12:1198-1202.
7. + T cells by rapid induction of multiple inhibitory receptors. J. Immunol. 184:4696-4707.
8. + T cells upregulate programmed death-1 expression during acute Friend retrovirus infection but are highly cytotoxic and control virus replication. J. Immunol. 187:3730-3737.
9. + T cells during chronic viral infection. Nature 439:682-687.
10. Okazaki T, Honjo T. 2006. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol. 27:195-201.
11. + T cell exhaustion during chronic viral infection. Immunity 27:670-684.
12. + regulatory T cells for immunologic self-tolerance and negative-control of immune responses. Annu. Rev. Immunol. 22:531-562.
13. + regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J. Virol. 78:2454-2459.
14. + T cells in vitro. AIDS Res. Hum. Retroviruses 23:438-450.
15. + T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J. Infect. Dis. 185:720-727.
16. + immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16:81-88.
17. Rouse BT, Sarangi PP, Suvas S. 2006. Regulatory T cells in virus infections. Immunol. Rev. 212:272-286.
18. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32.
19. Shevach EM. 2004. Regulatory/suppressor T cells in health and disease. Arthritis Rheum. 50:2721-2724.
20. + T regulatory cells. J. Immunol. 172: 4752-4761.
21. + Tcell responses in HIV-infected patients. Blood 104:3249-3256.
22. + T cells and reduces chronic retroviral set points. Proc. Natl. Acad. Sci. USA. 108:2420-2425.
23. + T cells by regulatory T cells during persistent retroviral infection. Immunity 20:293-303.
24. + regulatory T cells induced by chronic retroviral infection. Proc. Natl. Acad. Sci. U. S. A. 98:9226- 9230.
25. Zelinskyy G, Dietze KK, Husecken YP, Schimmer S, Nair S, Werner T, Gibbert K, Kershaw O, Gruber AD, Sparwasser T, Dittmer U. 2009. The regulatory T-cell response during acute retroviral infection is locally defined and controls the magnitude and duration of the virus-specific cytotoxic T-cell response. Blood 114:3199-3207.
26. + T cells can prevent murine AIDS progression. J. Immunol. 172:4917-4925.
27. + T cells in the pathogenesis of murine AIDS. J. Virol. 80:5777-5789.
28. + T regulatory cell depletion and PD-1 blockade. J. Virol. 85:13342-13353.
29. LaFace D, Talmadge J. 2011. Meeting report: regulatory myeloid cells. Int. Immunopharmacol. 11:780-782.
30. Ostrand-Rosenberg S. 2010. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59:1593-1600.
31. Peranzoni E, Zilo S, Marigo I, Dolcetti L, Zanovello P, Mandruzzato S, Bronte V. 2010. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22:238-244.
32. Youn J, Gabrilovich DI. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40:2969-2975.
33. + cells, suppressor cells, affect the immune response during Theiler's virus-induced demyelinating disease. J. Immunol. 183:6971-6980.
34. Cripps JG, Gorham JD. 2011. MDSC in autoimmunity. Int. Immunopharmacol. 11:789-793.
35. Cripps JG, Wang J, Maria A, Blumenthal I, Gorham JD. 2010. Type 1 T helper cells induce the accumulation of myeloid-derived suppressor cells in the inflamed Tgf 1 knockout mouse liver. Hepatology 52:1350-1359.
36. Haile LA, Von Wasielewski R, Gamrekelashvili J, Kruger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF. 2008. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 135:871-881.
37. Nicholson LB, Raveney BJ, Munder M. 2009. Monocyte dependent regulation of autoimmune inflammation. Curr. Mol. Med. 9:23-29.
38. + Ly-6C(hi) monocytes are crucial for the effector phase of autoimmunity in the central nervous system. Brain 132:2487-2500.
39. + Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J. Immunol. 179:5228-5237.
40. Bak SP, Alonso A, Turk MJ, Berwin B. 2008. Murine ovarian cancer vascular leukocytes require arginase-1 activity for T cell suppression. Mol. Immunol. 46:258-268.
41. Bronte V, Zanovello P. 2005. Regulation of immune responses by Larginine metabolism. Nat. Rev. Immunol. 5:641-654.
42. Greten TF, Manns MP, Korangy F. 2011. Myeloid derived suppressor cells in human disease. Int. Immunopharmacol. 11:802-807.
43. Kusmartsev S, Gabrilovich DI. 2003. Inhibition of myeloid cell differentiation in cancer: the role of reactive oxygen species. J. Leukoc. Biol. 74:186-196.
44. Lejeune P, Lagadec P, Onier N, Pinard D, Ohshima H, Jeannin JF. 1994. Nitric oxide involvement in tumor-induced immunosuppression. J. Immunol. 152:5077-5083.
45. Mazzoni A, Bronte V, Visintin A, Spitzer JH, Apolloni E, Serafini P, Zanovello P, Segal DM. 2002. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168:689-695.
46. Al-Ramadi BK, Brodkin MA, Mosser DM, Eisenstein TK. 1991. Immunosuppression induced by attenuated Salmonella. Evidence for mediation by macrophage precursors. J. Immunol. 146:2737-2746.
47. Gabrilovich DI, Nagaraj S. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9:162-174.
48. + myeloid cells inhibit development of antifungal Th 1 immunity in mice with candidiasis. J. Immunol. 169:3180-3190.
49. + immature myeloid suppressor cells. Int. Immunol. 14:1125-1134.
50. + myeloid cells and anergy of T lymphocytes participate in hyporesponsiveness of the lung-associated immune system during acute toxoplasmosis. Infect. Immun. 72:5487-5492.
51. Brys L, Beschin A, Raes G, Hassanzadeh Ghassabeh G, Noel W, Brandt J, Brombacher F, De Baetselier P. 2005. Reactive oxygen species and 12/15-lipoxygenase contribute to the antiproliferative capacity of alternatively activated myeloid cells elicited during helminth infection. J. Immunol. 174:6095-6104.
52. + cells: a potential mechanism for immune polarization in helminth infections. J. Immunol. 167:5294-5303.
53. Gobert AP, Akhtar M, Mendez GL, Newton JC, Cheng Y, Mobley LT. 2001. Helicobacter pylori arginase inhibits nitric oxide production by eukaryotic cells: a strategy for bacterial survival. Proc. Natl. Acad. Sci. USA. 98:13844-13849.
54. Vincendeau P, Gobert AP, Daulouede S, Moynet D, Djavad Mossalayi M. 2003. Arginases in parasitic diseases. Trends Parasitol. 19:9-12.
55. Jeisy-Scott V, Davis WG, Patel JR, Bowzard JB, Shieh W, Zaki SR, Katz JM, Sambhara S. 2011. Increased accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. PLoS One 6:e25242. doi:10.1371/journal.pone.0025242.
56. Chen S, Akbar SMF, Abe M, Hiasa Y, Onji M. 2011. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. Clin. Exp. Immunol. 166:134-142.
57. Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R. 2011. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide. Mol. Ther. 19:140-149.
58. Walker JD, Sehgal I, Kousoulas KG. 2011. Oncolytic herpes simplex virus 1 encoding 15-prostaglandin dehydrogenase mitigates immune suppression and reduces ectopic primary and metastatic breast cancer in mice. J. Virol. 85:7363-7371.
59. Vollbrecht T, Stirner R, Tufman A, Roider J, Huber RM, Bogner JR, Lechner A, Bourquin C, Draenert R. 2012. Chronic progressive HIV-1 infection is associated with elevated levels of myeloid-derived suppressor cells. AIDS 26:F31-F37.
60. Buller RML, Yetter RA, Fredrickson TN, Morse HC, III. 1987. Abrogation of resistance to severe mousepox in C57BL/6 mice infected with LP-BM5 murine leukemia viruses. J. Virol. 61:383-387.
61. Cerny AA, Hugin W, Hardy RR, Hayakawa K, Zinkernagel RM, Makino M, Morse HC, III. 1990. B cells are required for induction of T cell abnormalities in a murine retrovirus-induced immunodeficiency syndrome. J. Exp. Med. 171:315-320.
62. Klinken SP, Fredrickson TN, Hartley JW, Yetter RA, Morse HC, III. 1988. Evolution of B cell lineage lymphomas in mice with a retrovirusinduced immunodeficiency syndrome, MAIDS. J. Immunol. 140:1123-1131.
63. Klinman DM, Morse HC, III. 1989. Characteristics of B cell proliferation and activation in murine AIDS. J. Immunol. 142:1144-1149.
64. Legrand E, Daculsi R, Duplan JF. 1981. Characteristics of the cell populations involved in extrathymic lymphosarcoma induced in C57BL/6 mice by RadLV-RS. Leuk. Res. 5:223-233.
65. Morse HC, III, Yetter RA, Via CS, Hardy RR, Cerny A, Hayakawa K, Hugin AW, Miller MW, Homes KL, Shearer GM. 1989. Functional and phenotypic alterations in T cell subsets during the course of MAIDS, a murine retrovirus-induced immunodeficiency syndrome. J. Immunol. 143:844-850.
66. Mosier DE, Yetter RA, Morse HC, III. 1987. Functional T lymphocytes are required for a murine retrovirus-induced immunodeficiency disease (MAIDS). J. Exp. Med. 165:1737-1742.
67. Pattengale PK, Taylor CR, Twomey P, Hill S, Jonasson J, Beardsley T, Haas M. 1982. Immunopathology of B cell lymphomas induced in C57BL/6 mice by dual-tropic murine leukemia virus (MuLV). Am. J. Pathol. 107:362-377.
68. Simard C, Klein SJ, Mak T, Jolicoeur P. 1997. Studies of the susceptibility of nude, CD4 knockout, and SCID mutant mice to the disease induced by the murine AIDS defective virus. J. Virol. 71:3013-3022.
69. + T cells are required for development of a murine retrovirus-induced immunodeficiency syndrome (MAIDS). J. Exp. Med. 168:623-635.
70. Green KA, Crassi KM, Laman JD, Schoneveld A, Strawbridge RR, Foy TM, Noelle RJ, Green WR. 1996. Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice. J. Virol. 70:2569-2575.
71. Green KA, Noelle RJ, Green WR. 1998. Evidence for a continued requirement for CD40/CD40ligand (CD154) interactions in the progression of LP-BM5 retrovirus-induced murine AIDS. Virology 241:260-268.
72. Green KA, Noelle RJ, Durell BG, Green WR. 2001. Characterization of the CD154-positive and CD40-positive cellular subsets required for pathogenesis in retrovirus-induced murine immunodeficiency. J. Virol. 75:3581-3589.
73. Yu P, Morawetz RA, Chattopadhyay S, Makino M, Kishimoto T, Kikutani H. 1999. CD40-deficient mice infected with the defective murine leukemia virus LP-BM5def do not develop murine AIDS but produce IgE and IgG1 in vivo. Eur. J. Immunol. 29:615-625.
74. Green KA, Ahonen CL, Cook WJ, Green WR. 2004. CD40-associated TRAF 6 signaling is required for disease induction in a retrovirusinduced murine immunodeficiency. J. Virol. 78:6055-6060.
75. Kuhné MR, Robbins M, Hambor JE, Mackey MF, Kosaka Y, Nishimura T, Gigley JP, Noelle RJ, Calderhead DM. 1997. Assembly and regulation of the CD40 receptor complex in human B cells. J. Exp. Med. 186:337-342.
76. Pullen SS, Dang TT, Crute JJ, Kehry MR. 1999. CD40 signaling through tumor necrosis factor receptor-associated factors (TRAFs). Binding specificity and activation of downstream pathways by distinct TRAFs. J. Biol. Chem. 274:14246-14254.
77. Pullen SS, Miller HG, Everdeen DS, Dang TT, Crute JJ, Kehry MR. 1998. CD40-tumor necrosis factor receptor-associated factor (TRAF) interactions: regulation of CD40 signaling through multiple TRAF binding sites and TRAF hetero-oligomerization. Biochemistry 37:11836-11845.
78. Green KA, Cook WJ, Sharp AH, Green WR. 2002. The CD154/CD40 interaction required for retrovirus-induced murine immunodeficiency syndrome is not mediated by upregulation of the CD80/CD86 costimulatory molecules. J. Virol. 76:13106-13110.
79. + T cell receptor ligation needed? Virology 360:58-71.
80. Gaur A, Green WR. 2005. Role of a cytotoxic-T lymphocyte epitopedefined, alternative gag open reading frame in the pathogenesis of a murine retrovirus-induced immunodeficiency syndrome. J. Virol. 79:4308-4315.
81. Green KA, Okazaki T, Honjo T, Cook WJ, Green WR. 2008. The programmed death-1 and interleukin-10 pathways play a downmodulatory role in LP-BM5 retrovirus-induced murine immunodeficiency syndrome. J. Virol. 82:2456-2469.
82. Kuhn R, Lohler DJ, Rennick D, Rajewsky K, Muller W. 1993. Interleukin- 10-deficient mice develop chronic enterocolitis. Cell 75:263-274.
83. Laubach VE, Shesely EG, Smithies O, Sherman PA. 1995. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharideinduced death. Proc. Natl. Acad. Sci. USA. 92:10688-10692.
84. Nishimura H, Minato N, Nakano T, Honjo T. 1998. Immunological studies on PD-1-deficient mice: implication of PD-1 as a negative regulator for B cell responses. Int. Immunol. 10:1563-1572.
85. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH. 2005. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202:231-237.
86. Rowe WP, Pugh WE, Hartley JW. 1970. Plaque assay techniques for murine leukemia viruses. Virology 42:1136-1142.
87. Cook WJ, Green KA, Obar JJ, Green WR. 2003. Quantitative analysis of LP-BM5 murine leukemia retrovirus RNA using real-time RT-PCR. J. Virol. Methods 108:49-58.
88. Aziz DC, Hanna Z, Jolicoeur P. 1989. Severe immunodeficiency disease induced by a defective murine leukemia virus. Nature 338:505-508.
89. Chattopadhyay SK, Morse HC, III, Makino M, Ruscetti SK, Hartley JW. 1989. A defective virus is associated with induction of a murine retrovirus-induced immunodeficiency syndrome, MAIDS. Proc. Natl. Acad. Sci. USA. 86:3862-3866.
90. Hartley JW, Fredrickson TN, Yetter RA, Makino M, Morse HC, III. 1989. Retrovirus-induced murine acquired immunodeficiency syndrome: natural history of infection and differing susceptibility of inbred mouse strains. J. Virol. 63:1223-1230.
91. Haas M, Meshorer A. 1979. Reticulum cell neoplasms induced in C57BL/6 mice by cultured virus grown in stromal hematopoietic cell lines. J. Natl. Cancer Inst. 63:427-439.
92. Huang M, Simard C, Jolicoeur P. 1989. Immunodeficiency and clonal growth of target cells induced by helper-free defective retrovirus. Science 246:1614-1617.
93. Mosier DE, Yetter RA, Morse HC, III. 1985. Retroviral induction of acute lymphoproliferative disease and profound immunosuppression in adult C57BL/6 mice. J. Exp. Med. 161:766-784.
94. +T-regulatory cells. Int. Immunopharmacol. 11:1205-1210.
95. Knoetig SM, Torrey TA, Naghashfar Z, McCarty T, Morse HC, III. 2002. CD19 signaling pathways play a major role for murine AIDS induction and progression. J. Immunol. 169:5607-5614.
96. Benson MJ, Erickson LD, Gleeson MW, Noelle RJ. 2007. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr. Opin. Immunol. 19:275-280.
97. kB, IL-6, and IgE in human B lymphocytes. J. Immunol. 161:1738-1742.
98. Rush JS, Hodgkin PD. 2001. B cells activated via CD40 and IL-4 undergo a division burst but require continued stimulation to maintain division, survival and differentiation. Eur. J. Immunol. 31:1150-1159.
99. Murdoch C, Muthana M, Coffelt SB, Lewis CE. 2008. The role of myeloid cells in the promotion of tumor angiogenesis. Nat. Rev. Cancer 8:618-631.
100. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. 2009. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J. Leukoc. Biol. 85:996-1004.
101. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. 2007. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J. Immunol. 179:977-983.
102. Carlson TL, Green KA, Green WR. 2010. Alternative translational reading frames as a novel source of epitopes for an expanded CD8 T-cell repertoire: use of a retroviral system to assess the translational requirements for CTL-recognition and lysis. Viral Immunol. 23:577-583.
103. + T cells directed against a cryptic epitope derived from a retroviral alternative reading frame confer disease protection. J. Immunol. 176:2470-2745.
104. Ho O, Green WR. 2006. Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J. Immunol. 77:8283-8289.
105. Huang M, Jolicoeur P. 1994. Myristylation of Pr60gag of the murine AIDS-defective virus is required to induce disease and notably for the expansion of its target cells. J. Virol. 68:5648-5655.
106. Mayrand SM, Green WR. 1998. Nontraditionally derived CTL epitopes: exceptions that prove the rules? Immunol. Today 19:551-556.
107. Mayrand SM, Healy PA, Torbett BE, Green WR. 2000. Anti-gag cytolytic T lymphocytes specific for an alternative translational reading frame-derived epitope and resistance versus susceptibility to retrovirusinduced murine AIDS in F1 mice. Virology 272:438-449.
108. Mayrand SM, Schwarz DA, Green WR. 1998. An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency causing retrovirus. J. Immunol. 160:39-50.